PYC Therapeutics Advances ADOA Drug to Human Trials
Company Announcements

PYC Therapeutics Advances ADOA Drug to Human Trials

PYC Therapeutics Limited (AU:PYC) has released an update.

PYC Therapeutics Limited has announced positive GLP toxicology study results for PYC-001, its novel drug candidate targeting Autosomal Dominant Optic Atrophy (ADOA), clearing the way for human clinical trials. The drug has shown effectiveness in both ‘retina in a dish’ models and animal studies, with no adverse events at the highest doses tested. With these successful outcomes, the company is set to submit a regulatory application to commence human trials, aiming for initial safety and efficacy data by 2025 and a New Drug Application in 2028.

For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!